Clinical Trial Update: Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ALLN-177 for reducing urinary oxalate in patients with hyperoxaluria and kidney stones has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria
• Kidney Stones
• Nephrolithiasis

Drugs mentioned

• ALLN-177

Snippet

Sponsor: Allena Pharmaceuticals | Conditions: Secondary Hyperoxaluria, Nephrolithiasis | Phase 2 | Status: COMPLETED